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Abstract. The dibromido analogue of cisplatin, cis-PtBr2(NH3)2 (cisPtBr2 
hereafter), has been prepared and characterised. Its solution behaviour in 
standard phosphate buffer, at pH 7.4, was investigated 
spectrophotometrically and found to reproduce quite closely that of 
cisplatin; indeed, progressive sequential release of the two halide ligands 
typically occurs as in the case of cisplatin, with a roughly similar kinetics. 
Afterward, patterns of reactivity toward model proteins and standard 
ctDNA were explored and the nature of the resulting interactions 
elucidated. The antiproliferative properties were then evaluated in four 
representative cancer cell lines, namely A549 (human lung cancer), 
HCT116 (human colon cancer), IGROV-1 (human ovarian cancer) and 
FLG 29.1 (human acute myeloid leukaemia). Cytotoxic properties in line 
with those of cisplatin were highlighted. From these studies an overall 
chemical and biological profile emerges for cisPtBr2 closely matching 
that of cisplatin; the few slight, but meaningful differences that were 
underscored might be advantageously exploited for clinical application. 
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Introduction 
 Cisplatin is a leading and established anticancer compound in 
widespread clinical use. It is very effective against a few cancer types 
such as testicular and ovarian cancer but scarcely active against other 
important and more frequent solid tumors such as colorectal, ovarian 
and lung cancer (De simone et al. 1986; Wang and Wu 2006; Rosell 
2002) . While thousands of analogues of cisplatin have been prepared 
and tested so far, quite surprisingly the immediate parent Pt 
compounds that are obtained through simple replacement of the two 
chlorides with different halides as metal ligands (in particular the 
diiodido and dibromido derivatives) were poorly investigated.  
Most likely, this situation arises from the early misconception 
and/or generalisation that chloride replacement with other halides 
may result into substantial loss of the anticancer activity (Wilson and 
Lippard 2014; Johnstone et al. 2014; Cleare and Hoeschele 1973). 
These arguments led us to explore this kind of modification in a more 
systematic way and analyse its chemical and biological consequences. 
Recently, we demonstrated that the diiodido analogue of 
cisplatin manifests truly interesting biological properties and warrants 
a more extensive pharmacological evaluation (Marzo et al. 2015). 
This encouraging result prompted us to prepare and evaluate even the 
dibromido analogue of cisplatin (Fig.1). Accordingly, we report here 
the synthesis and chemical characterisation of cisPtBr2 as well as an 
initial and comparative assessment of its biological and 
pharmacological profile. 
 
Figure 1. Structure of cisplatin and its dibromido analogue. 
Materials and methods 
 
Chemistry of cis-PtBr2(NH3)2, synthesis and characterisation 
 
The synthesis of this Pt complex was performed through a slight 
modification of Dhara’s synthesis for cisplatin (Dhara 1970). A 
solution of 400 mg (2.4 mmol) of KI in 3 mL of water was added to 
an aqueous solution (5 mL) of 250 mg of K2[PtCl4] (0.6 mmol) which 
was quantitatively converted into a dark solution containing K2[PtI4] 
after five minutes of stirring at room temperature. Then the addition 
of two equivalents of ammonium hydroxide as a 40% solution results 
in the separation of cis-PtI2(NH3)2 as a bright yellow  compound, 
leaving behind a colorless solution. The solid was filtered off and 
thoroughly washed with water (yield 90%).   
A suspension of 200 mg of cis-PtI2(NH3)2  (0.41 mmol) in water 
(5mL) was mixed with a solution of AgNO3 (0.82 mmol) in water 
(1,5 mL) and stirred in the dark (40ºC) until a pale yellow solution 
was formed over the suspension. The AgI formed was then filtered 
off using neutral celite over a solution of two equivalents of KBr in 7 
mL of water. The colorless solution was stored until orange 
crystalline precipitation was observed. The bright orange crystals of 
cis-PtBr2(NH3)2 were filtered off, washed with water and dried in air. 
Yield was 25%. Purity of the product was assessed through elemental 
analysis of C, N and H [calculated C: 0%, H: 1.45%, N: 7.20%, 
experimental: C: 0,54%, H: 1.45%, N: 7.18%], 1H, 195Pt NMR and IR 
analysis (see SI). Cis geometry was checked as described in 
(Nakamoto 1997). Solution behaviour of cis-PtBr2(NH3)2 was assessed 
through spectrophotometric experiments performed with a Varian 
Cary 50 Bio UV-Vis spectrophotometer (1 cm pathlength quartz cell) 
in buffered solutions without the use of DMSO and NaCl. A solution 
of the complex (10−4 M) was prepared in 50 mM phosphate buffer  at 
pH = 7.4.  The absorbance was monitored in the wavelength range 
between 200 and 800 nm for 72 h at 25° C. 
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Log P determination 
 
The octanol–water partition coefficients for cisPtBr2 was determined 
by modification of the reported shake flask method (Marzo et al. 
2015). Water (50 mL, distilled after Milli-Q purification) and n-
octanol (50 mL) were shaken together for 72 h to allow saturation of 
both phases. Solution of the complex was prepared in the aqueous 
phase (3 × 10−3 M) and an equal volume of octanol was added. 
Biphasic solutions were mixed for ten minutes and then centrifuged 
for five minutes at 6000 rpm to allow separation. Concentration in 
both phases was determined by UV-VIS. Reported logP is defined as 
log [complex]oct / [complex]wat. Final value was reported as the mean 
of three determinations. 
  
Electrospray mass spectrometry, interaction with lysozyme 
 
A solution of cis-PtBr2(NH3)2 (10-4 M) was incubated with lysozyme 
(3:1 metal/protein ratio) for 72 h at 37° C in 20 mmol L-1 ammonium 
acetate at pH=6.8. ESI MS spectra were recorded after 24 and 72 h. 
After a 20-fold dilution with water, ESI MS spectra have been 
recorded by direct introduction at 5 μl min-1 flow rate in an Orbitrap 
high-resolution mass spectrometer (Thermo, San Jose, CA, USA), 
equipped with a conventional ESI source. The working conditions 
were the following: spray voltage 3.1 kV, capillary voltage 45 V, 
capillary temperature 220°C, tube lens voltage 230 V. The sheath and 
the auxiliary gases were set, respectively, at 17 (arbitrary units) and 1 
(arbitrary units). For acquisition, Xcalibur 2.0. software (Thermo) 
was used and monoisotopic and average deconvoluted masses were 
obtained by using the integrated -Xtract tool. For spectrum 
acquisition, a nominal resolution (at m/z 400) of 100,000 was used. 
 
Circular Dichroism experiments, interaction with ctDNA 
 
CD spectra were measured with a Jasco J-715 spectropolarimeter 
with the following conditions: scan speed 50 nm/min; response 1 sec; 
data pitch 0.1 nm; bandwidth 2.0 nm; 8 accumulations. Calf thymus 
DNA (ctDNA) 52.0 µM in phosphate buffer 50 mM, pH=7.4 was 
additioned with cis-PtBr2(NH3)2 2.3 mM in H2O or cisplatin 1.0 mM 
in H2O, to 0.5:1 and 1:1 molar ratio directly in a 1-cm quartz 
cylindrical cell, volume 2.5 ml. Concentrations and molar ratios are 
indicated per base. All samples (except one, see results) were 
incubated at room temperature (22°C) for 72h before measurement.  
The ctDNA had a base-pair length of ca. 800, obtained with a 
standardised procedure by sonication (Biver et al. 2003). The DNA 
concentration was checked by absorbance measurement at 260 nm 
(0.34 u.A., 1 cm cell). Phosphate buffer was used in all case to 
measure the blank spectrum. 
 
Cellular studies 
 
Cell cultures. A549 cells were cultured in DMEM High glucose 
(Euroclone; Milan, Italy) with 10% Fetal Bovine Serum (FBS) 
(Euroclone Defined; Euroclone; Milan, Italy). HCT-116, FLG 29.1 
and IGROV-1 were cultured in RPMI 1640 (Euroclone; Milan, Italy) 
with 10% Fetal Bovine Serum (FBS) (Euroclone Defined; Euroclone; 
Milan, Italy).  HCT116 cells were kindly provided by Dr R. Falcioni 
(Regina Elena Cancer Institute, Roma). All the cell lines were 
cultured at 37 °C in humidified atmosphere containing 5% CO2 in air. 
 
Pharmacology experiments. Cells were seeded in 96-well flat-
bottomed plates (Corning-Costar, Corning, NY, USA) at a cell 
density of 1 × 104 cells per well in either RPMI or DMEM complete 
medium. Drugs were used, after solubilization in water, without using 
DMSO, at concentrations ranging from 0 to 200µM. After 24 h, 
viable cells (determined by Trypan blue exclusion test) were counted 
in triplicate using a haemocytometer. Each experimental point 
represents the mean of a single experiment carried out in triplicate. 
  
Trypan blue exclusion test. Cells viability was assessed by the 
Trypan blue exclusion assay. In brief, 10 µL of a 0.4% trypan blue 
solution were added to 10 µL of cell suspensions in culture medium. 
The suspension was gently mixed and transferred to a 
haemocytometer. Viable and dead cells were identified and counted 
under a light microscope. Blue cells failing to exclude the dye were 
considered non viable, and transparent cells were considered viable. 
The percentage of viable cells was calculated on the basis of the total 
number of cells (viable plus non viable). The IC50 value (i.e. the dose 
that caused apoptosis of 50% of cells) was calculated by fitting the 
data points (after 24 h of incubation) with a sigmoidal curve using 
Calcusyn software (Biosoft, Cambridge, UK).  
 
Cell cycle analysis. The effect of cisplatin and cisPt(NH3)2Br2 on cell 
cycle distribution was assessed by flow cytometry after staining the 
cells with propidium iodide (PI). Briefly, the cells (5 × 105 cells per 
mL) were analysed prior to and after treatment with IC50s of both 
drugs for 24 h. The cells were harvested, washed with PBS and 
resuspended in 300 μL of propidium iodide staining solution and 
incubated at 4 °C in the dark for 20 minutes. DNA content of the 
cells was measured by BD FACSCanto (Becton Dickinson, Franklin 
Lakes, NJ, USA) Flow Cytometer and the cell population residing in 
each phase cell cycle phase was determined using ModFit LT 3.0 
analysis software (Verity Software House, Topsham, ME USA). 
 
Annexin/PI assay. The effects of the two compounds on FLG 29.1 
cells was investigated through the Annexin V/propidium iodide test 
(Annexin-VFLUOS staining kit; Roche Diagnostics, Mennheim, 
Germany). Cells were seeded at 2x105/well in 6-well plates and 
incubated with either drug for 24 hours. Cells were then harvested, 
washed with PBS, re-suspended in 100 μL of binding buffer and 
incubated with FITC-conjugated Annexin V and propidium iodide for 
15 min. Flow cytometry analysis was performed with BD 
FACSCanto (Becton Dickinson, Franklin Lakes, NJ, USA) and 
analysed with BD FACSDiva Software 6.1.3. Each experiment was 
performed in triplicate. 
 
Results and discussion 
 
Solution behaviour of cis-PtBr2(NH3)2, activation profile and logP 
determination 
 
cisPtBr2 shows an acceptable solubility in the reference phosphate 
buffer, at physiological pH; this allows to carry out experiments in 
the absence of DMSO or other organic solvents, thus avoiding 
potential interferences. Freshly prepared solutions of cis-PtBr2(NH3)2 
manifest typical absorption bands in the UV-visible, with a main 
band at 330 nm and a pronounced shoulder at 300 nm (Fig. 2a).  
These bands are tentatively assigned to a d-d and a LMCT 
transition, respectively, in analogy with other cisplatin analogs 
(Marzo et al. 2015). After dissolution of the study compound in the 
reference buffer, progressive spectral changes are observed that are 
ascribed to the progressive release of the two bromide ligands. The 
nature of the process and its kinetics are similar to what observed in 
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the case of cisplatin despite release of halides in the case of cisPtBr2 
appears to be slight slower than in case of cisplatin (see SI for details 
and numerical data on the hydrolysis processes). By comparative 
inspection of the spectral profiles of cisPtBr2 and cisplatin, monitored 
over 24 h, their progressive convergence was noticed, indicating that 
the final species are the same for both drugs (see SI for further 
details).  
Furthermore, log P determination was carried out on cisPtBr2 and a 
value of -1.04 was found. Remarkably this value is intermediate 
between those previously measured for cisplatin (-2.4) and cis-
PtI2(NH3)2 (-0.13) (Marzo et al. 2015), thus, being the dibromido 
analogue of cisplatin far more lipophilic than cisplatin itself, it is well 
conceivable that this difference may have some appreciable effect in 
terms of pharmacological activity.  
 
 
Figure 2. Time course spectra of cisPtBr2 10-4 M in 50mM phosphate buffer over 24 
h, RT. 
Mechanistic studies: biomolecular interactions 
To investigate the possible interactions occurring between 
cisPtBr2 and its potential biomolecular targets we first performed a 
few ESI MS experiments for samples where the study complex was 
incubated with the model protein lysozyme for increasing time 
intervals (Fig. 3).  
First attempts to characterise the protein metalation process 
through ESI MS detection were performed  by analysing samples 
after 24 h of incubation, but no clear evidence of adduct formation 
was gained. However, upon increasing the incubation time up to 72 h, 
under identical solution conditions, a number of peaks of higher 
molecular weight than the native protein, were instead observed that 
were straightforwardly assigned to metallodrug-lysozyme adducts.  
From careful inspection of the spectrum, it is evident that Pt 
coordination occurs through a mechanism that involves preferential 
detachment of halide ligands and full retention of ammonia ligands; 
assignments were validated by theoretical calculations (see SI for 
comparison between experimental and theoretical peaks). This kind 
of protein metalation strictly resembles that produced by cisplatin 
resulting in an adduct characterised by selective Pt coordination to 
His15 following the release of the two chloride ligands  (Casini et al. 
2007).  
Remarkably, this behaviour being in accord with cisplatin is in 
contrast with that of cisPtI2, where metalation of lysozyme occurs 
through protein binding of metal fragments resulting from 
preferential release of the ammonia ligands (Messori et al. 2012). 
Figure 3. Deconvoluted ESI MS spectra of lysozyme treated with 3 x 10-4 mol L-1 of 
cisPtBr2 recorded after 72 h of incubation at 37 °C, metal : protein ratio = 3:1; 
ammonium acetate buffer 20 mmol L-1 at pH=6.8. 
CD experiments, interaction with ctDNA 
Since nuclear DNA is believed to be the primary target for the 
pharmacological effect of cisplatin, (Siddik 2003) we next 
characterized the interaction of cisPtBr2 with calf thymus DNA 
through CD experiments, and compared the results with those of 
cisplatin. 
The CD spectrum of ctDNA, before addition of the drugs is in 
keeping with literature (Tamburro et al. 1977) (Fig. 4).  Addition of 
0.5 equiv of cis-PtBr2(NH3)2 did not lead to any immediate change in 
the CD spectrum (data not shown). However, after incubation at 22°C 
for 72 h, the spectrum changed appreciably showing clear differences 
on the whole wavelength range (Fig. 5). In particular, both CD bands 
at 280 and 250 nm increased in intensity, the first by about 15%. 
 
 
 
 
 
Figure 4. CD spectra of ctDNA without and with cis-PtBr2(NH3)2, 0.5 and 1 equiv, 
after 72 h incubation. 
Furthermore, no significant spectral changes were found after 
increasing the amount of complexes up to 1 equiv, being the two 
spectral profiles at 0.5 or 1 equiv  superimposable (Fig. 4). Evidence 
that cisPtBr2 interacts with ctDNA similarly to cisplatin derives from 
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the comparative analysis of the CD spectra of ctDNA after incubation 
with 1 equivalent of cisPtBr2 or cisplatin (Fig. 5). 
 
 
 
 
 
Figure 5. CD spectra of ctDNA with cis-PtBr2(NH3)2 and cisplatin, 1 
equivalent, after 72h incubation. 
Modification in the CD spectral profiles are well detectable, 
consistent and superimposable for the two complexes. A direct 
comparison with previous CD investigations on the ctDNA/cisplatin 
system (Tamburro et al. 1977; Sristava 1978)  is complicated by 
relevant differences in the applied solution conditions and in the 
nature of ctDNA samples (non-sonicated vs. sonicated). Qualitatively 
speaking, the differences observed upon binding occur in the same 
spectral regions and to a similar extent. However, our fragmented 
ctDNA (800 bp) shows a full enhancement of the main CD bands, 
already with 0.5 equivalent of ligand per base.  
 
Cellular effects 
We then investigated the effects of cisPtBr2 on cell vitality of a small 
panel of human cancer cell lines, applying the Trypan blue exclusion 
test according to the method described in the experimental section.  
The cancer cell panel included the following lines: A549 
(human lung cancer), HCT116 (human colon cancer), IGROV-1 
(human ovarian cancer) and FLG 29.1 (human acute myeloid 
leukaemia). These cells were exposed to increasing concentrations of 
the drug, in the 0–200 μM range, and treated for 24 hours; IC50 values 
were determined (Table 1). It is evident that cis-PtBr2(NH3)2 
produces cytotoxic effects almost superimposable to those of 
cisplatin in all the cancer cell lines. A slightly greater effect of 
cisPtBr2 compared to cisplatin was observed in FLG 29.1 leukaemia 
cells. These encouraging results led us to deepen our investigation.  
The effects of cisPtBr2 on cell cycle and apoptosis were further 
evaluated in FLG 29.1 cells. Upon  treatment with cis-PtBr2(NH3)2 a 
reduction in the percentage of cells in the G0/G1 phase accompanied 
by an increase in G2/M cells was observed. Such effect was more 
evident than that produced by cisplatin (see Figure 6). We next 
evaluated the effect of cis-PtBr2(NH3)2 on the induction of apoptosis 
by Annexin/PI test. As reported in Figure 7 cis-PtBr2(NH3)2 
determined a more evident pro-apoptotic effect compared to cisplatin, 
in FLG 29.1 cells (percentage of Annexin+/PI- cells: f 51.85±4.5 vs 
41.15±2.75, respectively). Finally, we determined the effects of either 
cisPtBr2 or cisplatin (both at 19 µM concentration) on proliferation of 
FLG 29.1 cells. Live cell number was monitored for 72 hours. As 
shown in Figure 8 the dibromido analogue impaired leukaemia cell 
proliferation even better than cisplatin, especially at longer 
incubation times.   
 
 
 
 
 
Table 1. Evaluation of IC50 on a panel of tumor cell lines. A549,FLG,HCT-116 and 
IGROV-1 cell lines were exposed to IC50 concentrations of cisplatin and cisPtBr2 for 
24 hours and cell viability was evaluated via Trypan Blue exclusion assay. Means 
and SDs are relative to one experiment mounted in triplicate.  
 
 
a)                                               b)                                    c) 
Figure 6. Effect of Cisplatin and cisPtBr2 on cell cycle of FLG cells (a=untreated). 
Effect of cisplatin (b) and of cisPtBr2 (c) given at their IC50s on cell cycle of FLG 
cells after 24h of treatment. The means and SEMs relative to two independent 
experiments are reported next to each representative panel. 
 
 
 
a)                                               b)                                    c) 
Figure 7. Effect of cisplatin and of cisPtBr2 given at their IC50s on the induction of 
apoptosis on FLG cells after 24h of treatment. The means and SEMs relative to two 
independent experiments are reported in each representative panel. a=untreated, 
b=cisplatin, c= cisPtBr2 
 
 
 
 
 
IC50 Cisplatin 
(µM) 
mean±SD 
IC50  cis-PtBr2(NH3)2 
(µM) 
mean±SD 
A549 8.61±1.26 10.08±1.26 
FLG 
29.1 
24.33±1.30 14.66±1.10 
HCT-
116 
20.04±1.65 28.28±5.39 
IGROV-
1 
24.12±0.85 25.63±0.43 
  
 
 
 
 
Figure 8: Effects of cisplatin (black dots) and  cisPtBr2 (black triangles) on FLG 
29.1 cell line proliferation during the passage of time given as the number of Trypan 
Blue negative cells. Drugs were added once a t=0. Data are means ± SD of two 
independent experiments.  
Discussion and Conclusions 
Cisplatin is one of the oldest and most used Pt-based anticancer drug 
with a long success story in the clinics since 1979. Yet, cisplatin 
shows some severe drawbacks that have triggered a lot of attention in 
the preparation and identification of new and hopefully more active 
and less toxic anticancer Pt drugs. 
Despite the intense investigations carried out in the field of Pt-
based drugs during the last three decades, the closest analogues of 
cisplatin, e.g. Pt complexes differing only in the chemical nature of 
the two halide ligands, were poorly studied. We have recently 
analysed the behaviour of the diiodido analogue of cisplatin (Marzo 
et al. 2015). Very interesting chemical and biological features of this 
compound emerged. Notably, the diiodido analogue turned out to 
have strong cytotoxic effects on different cancer cell lines in vitro, 
especially on those more resistant to cisplatin effects. Some 
peculiarities in the nature of the reaction of cisPtI2 with model 
proteins were also highlighted (Marzo et al. 2015). Here, we 
extended our investigation to the dibromido analogue, in order to 
have a deeper insight and more complete description of this topic. 
cisPtBr2 could be prepared quite easily according to the 
classical synthetic procedure of Dhara, with slight modifications. Its 
solution chemistry was explored in a standard physiological buffer 
and a behaviour very close to cisplatin emerged. Indeed, activation 
cis-PtBr2(NH3)2 occurs through progressive release of the two 
bromide ligands.  
When tested with a model protein (lysozyme) a platination 
pattern similar to cisplatin emerged, with protein coordination of 
[cisPt(NH3)2]2+ fragments. Even the process of platination of standard 
ctDNA (800 bp) was highly reminiscent of that of cisplatin and CD 
spectroscopy clearly proved the similar nature of those interactions. 
One equivalent of ligand (per base pair, 0.5 equiv per base) turned 
out to achieve full binding. The binding is similar for cis-PtBr2(NH3)2 
and cisplatin. Using our fragmented ctDNA, the effects of cisplatin 
are slightly different from those reported in the literature for non-
sonicated ctDNA (Tamburro et al. 1977; Sristava 1978).  
Cellular studies were performed on four different cancer cell 
lines. Cytotoxic effects were generally comparable to those produced 
by cisplatin (see LD50 values in Table 1), and even slightly higher in 
FLG 29.1 leukaemia cells. In the latter cells, cisPtBr2 turned out to 
trigger apoptosis, modulate cell cycle distribution and decrease cell 
proliferation, at the same extent, and even better than cisplatin. All 
these effects might be at least partially explained by the higher 
lipophilicity of the dibromido-analogue compared to cisplatin which 
could ensue in an increased cellular uptake (preliminary data are 
shown in SI). Also, even the possible small differences in the kinetic 
of halides release (see SI) may be invoked to play some role in the 
slight but meaningful differences in the pharmacological effect 
between cisplatin and its dibromide analogue.  
We believe that the findings outlined in this paper might be exploited 
for further preclinical studies of this analogue and for a full 
assessment of its pharmacological profile with respect to cisplatin. 
Indeed, as the two compounds are very similar in their overall 
chemical and biological profile, the slight differences here 
highlighted might translate into an effective therapeutic advantage 
and/or in a somewhat modified spectrum of anticancer actions for 
cisPtBr2  over  cisplatin.  
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